Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw,

Slides:

Advertisements

Similar presentations

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

Advertisements

Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations

Ian D. Molyneux, Tanya Moon, A. Kevin Webb, Alyn H. Morice

Treatment compliance in children and adults with Cystic Fibrosis

Dorene F. Balmer, Joan I. Schall, Virginia A. Stallings

Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis Stefanie Hennig, Karen McKay, Suzanna Vidmar, Katie O'Brien,

P. Whitaker, N. Shaw, J. Gooi, C. Etherington, S. Conway, D. Peckham

How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF? Sarah P. Cohen, David M. Orenstein

Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H

Megan R. Nelson, Craig R. Adamski, Audrey Tluczek

Successful treatment of cepacia syndrome

A review of renal disease in cystic fibrosis

Urinary incontinence in 9��16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group W.J. Browne, C.J. Wood, M.

Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study Doug L. Forrester, Alan J. Knox,

Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint D.R. VanDevanter, A. Yegin, W.J. Morgan,

Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis Marco Zampoli, Komala Pillay, Henri Carrara,

Laura Viviani, Baroukh M. Assael, Eitan Kerem

Cirrhosis and other liver disease in cystic fibrosis

John Widger, Sarath Ranganathan, Philip J. Robinson

The ease of breathing test tracks clinical changes in cystic fibrosis

Rate of improvement of CF life expectancy exceeds that of general population— Observational death registration study Matthew N. Hurley, Tricia M. McKeever,

Delayed publication of clinical trials in cystic fibrosis

Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,

Controlled clinical trials in cystic fibrosis — are we doing better?

Anju Anand, Elizabeth Tullis, Anne Stephenson, Preyanka Abhyankar

D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams

Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox

Cystic fibrosis mortality trend in Italy from 1970 to 2011

Claire Keating, Armeen D

Long-term daily high and low doses of azithromycin in children with cystic fibrosis: A randomized controlled trial S.K. Kabra, R. Pawaiya, Rakesh Lodha,

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Pulmonary nocardiosis in cystic fibrosis

A.H. Gifford Journal of Cystic Fibrosis

Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009 Yolanda P. Lillquist,

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

Inhalation solutions — Which ones may be mixed

Physiologic endpoints for clinical studies for cystic fibrosis

Sophia L. Markantonis, Anna Katelari, Eleni Pappa, Stavros Doudounakis

Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?

Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy G. Fitch, K. Williams,

Anastasios Lekkas, Khin M. Gyi, Margaret E. Hodson

Elliott C. Dasenbrook, Gregory S. Sawicki Journal of Cystic Fibrosis

Narelle S. Cox, Jennifer Follett, Karen O. McKay

Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis Geraint B. Rogers, Lucas R. Hoffman,

Gender differences in treatment adherence among youth with cystic fibrosis: Development of a new questionnaire Joän M. Patterson, Melanie Wall, Jerica.

Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale

Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005 F.A. Millar, N.J. Simmonds, M.E. Hodson Journal.

Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids Francis J. Gilchrist, A.

V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume

Comparing age of cystic fibrosis diagnosis and treatment initiation after newborn screening with two common strategies Don B. Sanders, Huichuan J. Lai,

H. White, A.M. Morton, S.P. Conway, D.G. Peckham

J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer

James H. Hull, Rachel Garrod, Timothy B. Ho, Ronald K. Knight, John R

Michael W. Konstan, David J. Pasta, Jeffrey S. Wagener, Donald R

Voriconazole therapy in children with cystic fibrosis

D.F. Waterhouse, A.M. McLaughlin, C.G. Gallagher

The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation C. Etherington,

Intravenous monthly pulse methylprednisolone treatment for ABPA in patients with cystic fibrosis Malena Cohen-Cymberknoh, Hannah Blau, David Shoseyov,

‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis

Beta-lactam allergy in adults with cystic fibrosis

Lutz Goldbeck, Sven Zerrer, Tim G. Schmitz Journal of Cystic Fibrosis

Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub

David Adeboyeku, Sandra Scott, Margaret E. Hodson

Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L

Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005 Donald R. VanDevanter, Eric P. Elkin,

Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis D.J. Touw, A.J. Knox,

Cystic fibrosis and pregnancy in the modern era: A case control study

R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis M.N. Hurley, A.H. Amin Ariff, C. Bertenshaw, J. Bhatt, A.R. Smyth Journal of Cystic Fibrosis Volume 11, Issue 4, Pages 288-292 (July 2012) DOI: 10.1016/j.jcf.2012.02.006 Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Flow diagram of patient/episode selection. Journal of Cystic Fibrosis 2012 11, 288-292DOI: (10.1016/j.jcf.2012.02.006) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 FEV1 change over the duration of an antibiotic treatment course with categorisation of antibiotic concordance (UoA — unit of analysis). Journal of Cystic Fibrosis 2012 11, 288-292DOI: (10.1016/j.jcf.2012.02.006) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 BMI change over the duration of an antibiotic treatment course with categorisation of antibiotic concordance (UoA — unit of analysis). Journal of Cystic Fibrosis 2012 11, 288-292DOI: (10.1016/j.jcf.2012.02.006) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Time to next exacerbation/course of iv antibiotics categorised by antibiotic concordance (UoA — unit of analysis). Journal of Cystic Fibrosis 2012 11, 288-292DOI: (10.1016/j.jcf.2012.02.006) Copyright © 2012 European Cystic Fibrosis Society. Terms and Conditions